# A Study to Evaluate the Efficacy of VVD-133214 in Combination With Pembrolizumab Compared With Pembrolizumab Alone in Participants With Advanced Cancer of the Colon or Rectum

Source: https://onco.cc/trials/nct07811193/  
OnCo record `nct07811193` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Pembrolizumab in colorectal cancer, run by Vividion Therapeutics, Inc., now recruiting.

## Summary

A Study to Evaluate the Efficacy of VVD-133214 in Combination With Pembrolizumab Compared With Pembrolizumab Alone in Participants With Advanced Cancer of the Colon or Rectum is a phase 2 interventional study registered as NCT07811193 by Vividion Therapeutics, Inc., with 140 participants planned, started 2026-09-11 and due to reach its primary completion in 2028-06-30. Interventions recorded: VVD-133214 and Pembrolizumab.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07811193
- Phase: 2
- Setting: A Phase 2, Randomized, Open-label Study of VVD-133214 in COmbination With Pembrolizumab Compared to Pembrolizumab Monotherapy in Participants With Advanced Colorectal Adenocarcinoma (CRC) Harboring Microsatellite Instability (MSI) and/or Deficient Mismatch Repair (DMMR)
- Sponsor: Vividion Therapeutics, Inc.
- Enrolled: 140

## Sources

- ClinicalTrials.gov NCT07811193: https://clinicaltrials.gov/study/NCT07811193

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/)
- drugs: [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- companies: [Bayer](https://onco.cc/companies/bayer/)

---
JSON: https://onco.cc/api/v1/entities/nct07811193.json